Today’s article highlights three biotech penny stocks to watch right now, including one that the author notes has “had an epic year so far”: It started the year trading under $1 and proceeded to go as high as $5.55 before recently being driven down to as low as $1.68 – and may now be experiencing a turnaround! For more on this particular stock and two more biotech penny stocks to watch right now, CLICK HERE.
A hematology drugmaker that could rise at least 60% and a gene therapy developer that could nearly double top the list of the favorite biotech stocks of a newly-hired analyst at Raymond James. Also making the list of top biotech stocks? A neurology stock, a hematology stock – and more. For a closer look at each of these biotech stocks, CLICK HERE.
When it comes to the S&P 500 and one of the ETFs that represents the overall biotech sector (the iShares Nasdaq Biotechnology ETF), the author of today’s article observes that “the paths of these two investments appear to be diverging.” Given this apparent divergence, he questions whether, despite all the recent medical news, biotech stocks have already had their run. For more, CLICK HERE.
“2020 will be remembered as the year of the biotech sector,” declares the author of today’s article, who proceeds to highlight two biotech stocks that Morgan Stanley is bullish on – and which have also earned “Strong Buy” consensus ratings from the analyst community at large. For these two biotech stocks with significant upside potential, CLICK HERE.
When it comes to the uncertainty that currently permeates the market as a result of the pandemic and impending election, the chief investment strategist at Oppenheimer is choosing to embrace it. As a result, today’s article takes a look at two specific stocks Oppenheimer is bullish on – and which its analysts believe have over 100% upside potential (792% in the case of one of the stocks!). For these two stocks – a clinical-stage biopharmaceutical company and a clinical-stage gene therapy company – CLICK HERE.
Both of the stocks highlighted in today’s article are clinical-stage biotechs, both are developing products to address the coronavirus pandemic (a vaccine in one case and a therapeutic in the other) – and both are “ultra-risky”. So what are the chances that either – or both – of these two ultra-risky stocks could make investors ultra wealthy? For more on these two stocks – one of which just made its market debut – CLICK HERE.
“Many investors, especially more aggressive traders, look at lower-priced stocks as a way to not only make some good money but to get a higher share count,” notes the author of today’s article. He proceeds to highlight five low-priced biotech and medtech stocks with significant upside potential to consider for very aggressive accounts. For these five stocks – including a clinical-stage biopharmaceutical company working on a potential blockbuster treatment for post-traumatic stress disorder – CLICK HERE.
One of the biotech stocks highlighted in today’s article is a well-established, large-cap name. The other is a far less established, small-cap player with no products currently on the market. What the two have in common, according to the author, is that both “have made significant breakthroughs — and could provide market-beating returns for many years to come as a result.” For these two biotech stocks to consider – one that currently dominates the cystic fibrosis market and one that is likely to disrupt the diabetes market – CLICK HERE.
In January, the small-cap biotech highlighted in today’s article received FDA approval for its treatment for childhood peanut allergy – and with peanut allergy being the most common food allergy in the U.S. (with cases of the condition rising rapidly) and the fact that this is currently the only FDA-approved treatment for the condition (thanks to a competitor encountering some regulatory roadblocks), this drug has the potential to become a blockbuster product. For more, CLICK HERE.
The solution to the substantial risks associated with biotech stocks (especially small biotech firms)? Biotech ETFs! Today’s article highlights six biotech ETFs to consider buying, noting that “Some provide well-rounded access to the space, while others acutely focus on certain aspects of the space, such as cancer treatments or drugs to battle infectious diseases.” For these six biotech ETFs, CLICK HERE.